CVS Health and FTC Staff Agree to Proposed Insulin Settlement

March 24, 2026 - 22:15

A significant development has emerged in the ongoing scrutiny of prescription drug costs, as a proposed agreement has been finalized between CVS Health and staff of the Federal Trade Commission. The settlement focuses on allegations concerning the business practices of CVS's pharmacy benefit manager (PBM) subsidiary, Caremark.

The FTC's investigation centered on how Caremark negotiated prices and rebates for insulin, a life-saving medication for millions of Americans with diabetes. Regulators have been examining whether certain PBM tactics, including complex rebate structures and formulary placements, unfairly inflate out-of-pocket costs for patients at the pharmacy counter.

While the specific financial terms and conditions of the proposed settlement remain confidential pending final approval, the resolution marks a potential turning point. It signals heightened regulatory pressure on the often-opaque PBM industry, which acts as a middleman between drug manufacturers, insurers, and pharmacies. Caremark has maintained that it did not engage in any wrongdoing throughout the process.

The proposed settlement now awaits a final vote by the full panel of FTC commissioners. If approved, it would conclude this particular investigation and likely impose new operational requirements on Caremark, potentially setting a precedent for how PBMs manage insulin and other critical medications. The outcome is being closely watched by patient advocates, lawmakers, and the healthcare industry as a bellwether for future enforcement actions aimed at reducing drug costs.